Skip to main content
Caplight Logo









Flindr Therapeutics

Flindr Therapeutics

Private
OssHealthcare & Life Scienceshttps://flindrtx.com/

Last Round

Series A

Apr 24, 2024

Total Funding Raised

$21.4M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Flindr Therapeutics is a biotechnology company developing a pipeline of first-in-class small molecule inhibitors for the precision treatment of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Application

Keywords

small molecule inhibitorsprecision oncologyfirst-in-class therapiesRNF31 inhibitortarget discoverydrug discovery enginepre-clinical biotechE3 ubiquitin ligasedrug licensingreverse translationHOIP inhibitorB-cell lymphoma treatmentovarian cancer treatmentAI-enabled drug discoveryIND applicationstructure-based drug design

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Flindr Therapeutics Comparables

Compare Flindr Therapeutics with similar companies based on industry and business-model similarity.

Flindr Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Outrun Therapeutics
84%
Eisbach Bio GmbH
78%
Light Horse Therapeutics
77%

Flindr Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 24, 2024

Key People

Founding team and executive leadership

Maarten Ligtenberg

Chief Executive Officer at Flindr Therapeutics

Executive Team

Flindr Therapeutics Investors

Notable investors and investment history

Flindr Therapeutics investors
InvestorRounds
Brabantse Ontwikkelings MaatschappijSeed, Series A
Swanbridge CapitalSeed, Series A
Innovatiefonds Noord-HollandSeed
V-Bio VenturesSeries A
Oncode InstituteSeed, Series A
PMVSeries A
Johnson & Johnson Innovation - JJDC, Inc.Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 1, 2026

    Grew 17% QoQ from 18 to 21 employees.

  • Jan 24, 2026

    Monthly visitors increased 505% MoM, from 74 to 448.

Flindr Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Flindr Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Flindr Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersOss
Employee Range21
Year Founded2020
Last FundingApr 24, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?